Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma

Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.

Inclusion Criteria:

• multiple myeloma
• stage I (Salmon & Durie)
• no cytoreductive pre-treatment

Exclusion Criteria:

• myeloma stages II-III
• asecretory disease